School of Biological Sciences, National Institute of Science Education and Research, Institute of Physics Campus, Sainik School, Sachivalaya marg, Bhubaneswar, India.
Crit Rev Ther Drug Carrier Syst. 2013;30(6):469-93. doi: 10.1615/critrevtherdrugcarriersyst.2013007346.
The potency of biomolecules assures therapy for as well as prevention of many disorders. However, their stability and delivery to the site of action remain a major challenge for successful therapeutic application. With advantages of nanoformulations, such as systemic environmental protection, controlled and site specific release, many of these bio-molecules have found their place in preventive, curative, or immunization-based therapies. Nanoformulations have indeed become a boon for the delivery of biomolecules with such challenges. Among biomolecules, small interfering RNA (siRNA)-based therapeutics has broad range of applications for disorders that may be pathological, metabolic, or physiological. However, certain challenges with respect to biological and delivery constraints need a priori consideration. From this perspective, liposomal delivery has made substantial progress to meet most of the delivery-related (pharmacokinetic) problems associated with siRNA. Furthermore, need-based development has led to the evolution of variants of liposomes. In this review we focus on the scope of siRNA and the trend of rationalized development of liposomal variants to explore its potential therapeutic implication.
生物分子的效力确保了对许多疾病的治疗和预防。然而，它们的稳定性和递送到作用部位仍然是成功治疗应用的主要挑战。由于纳米制剂具有全身环境保护、控制和靶向释放等优势，许多这些生物分子已经在预防、治疗或基于免疫的治疗中找到了自己的位置。纳米制剂确实为具有这些挑战的生物分子的递药带来了福音。在生物分子中，基于小干扰 RNA（siRNA）的治疗方法在可能是病理、代谢或生理的疾病方面具有广泛的应用。然而，与生物和递药限制相关的某些挑战需要事先考虑。从这个角度来看，脂质体递药在解决与 siRNA 相关的大多数递药相关（药代动力学）问题方面取得了实质性进展。此外，基于需求的开发导致了脂质体变体的发展。在这篇综述中，我们重点讨论了 siRNA 的范围和合理开发脂质体变体的趋势，以探索其潜在的治疗意义。
